{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:09:57Z","timestamp":1787501397725,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40268-024-00487-1","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T14:02:19Z","timestamp":1726668139000},"page":"391-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Case Report of JAK Inhibitors Therapy for Adult-Onset Still\u2019s Disease with Persistent Pruritic Lesions"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8960-172X","authenticated-orcid":false,"given":"Li","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingxiu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"issue":"6","key":"487_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","volume":"79","author":"Q Hu","year":"2020","unstructured":"Hu Q, Wang M, Jia J, et al. Tofacitinib in refractory adult-onset still\u2019s disease: 14 cases from a single centre in China. Ann Rheum Dis. 2020;79(6):842\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216699.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"487_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/rheumatology\/key414","volume":"58","author":"C Ladhari","year":"2019","unstructured":"Ladhari C, Jorgensen C, Pers YM. Treatment of refractory adult onset Still\u2019s disease with combination anakinra and baricitinib therapy. Rheumatology (Oxford). 2019;58(4):736\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/key414.","journal-title":"Rheumatology (Oxford)"},{"key":"487_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40268-023-00417-7.2023","volume":"23","author":"Z Sun","year":"2023","unstructured":"Sun Z, Li R, Wang Y, et al. Efficacy of baricitinib in patients with refractory adult-onset still\u2019s disease. Drugs R&D. 2023;23:109\u201320. https:\/\/doi.org\/10.1007\/s40268-023-00417-7.2023.","journal-title":"Drugs R&D"},{"issue":"3","key":"487_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133\u201345. https:\/\/doi.org\/10.1038\/s41584-021-00726-8.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"487_CR5","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult still\u2019s disease. J Rheumatol. 1992;19(3):424\u201330.","journal-title":"J Rheumatol"},{"issue":"4","key":"487_CR6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","volume":"62","author":"L Gillard","year":"2023","unstructured":"Gillard L, Pouchot J, Cohen-Aubart F, et al. JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2023;62(4):1594\u2013604. https:\/\/doi.org\/10.1093\/rheumatology\/keac440.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"487_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001246","volume":"6","author":"M Kacar","year":"2020","unstructured":"Kacar M, Fitton J, Gough AK, et al. Mixed results with baricitinib in biological-resistant adult-onset Still\u2019s disease and undifferentiated systemic autoinflammatory disease. RMD Open. 2020;6(2): e001246. https:\/\/doi.org\/10.1136\/rmdopen-2020-001246.","journal-title":"RMD Open"},{"issue":"4","key":"487_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/03009742.2020.1729405","volume":"49","author":"M Honda","year":"2020","unstructured":"Honda M, Moriyama M, Kondo M, et al. Tofacitinib-induced remission in refractory adult-onset Still\u2019s disease complicated by macrophage activation syndrome. Scand J Rheumatol. 2020;49(4):336\u20138. https:\/\/doi.org\/10.1080\/03009742.2020.1729405.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"487_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2217\/imt-2023-0037","volume":"15","author":"F Navarro-Trivi\u00f1o","year":"2023","unstructured":"Navarro-Trivi\u00f1o F, Alcantara-Luna S, Dom\u00ednguez-Cruz J, et al. Upadacitinib for moderate to severe atopic dermatitis. Immunotherapy. 2023;15(11):799\u2013808. https:\/\/doi.org\/10.2217\/imt-2023-0037.","journal-title":"Immunotherapy"},{"issue":"16","key":"487_CR10","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2147\/ccid.S424310","volume":"14","author":"J Xia","year":"2023","unstructured":"Xia J, Jiang G. A report of eruptive pruritic papular porokeratosis treated with abrocitinib. Clin Cosmet Investig Dermatol. 2023;14(16):2223\u20137. https:\/\/doi.org\/10.2147\/ccid.S424310.","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00487-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00487-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00487-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T08:06:18Z","timestamp":1728374778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00487-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00487-1","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"22 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed according to the Declaration of Helsinki and approved by the ethics committee of the Dermatology Hospital of Jiangxi Province. Informed consent for this patient was obtained. The ethics approval number, KY2023-33-01, was granted on June 16, 2023.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Patient provided consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of the images in Fig.\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The original data are available upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors participated in the treatment and reporting of this case. Li Tang and Hongjian Shi followed up with the patient and wrote the text. Xiaobing Wang and Chun Huang helped to edit the manuscript. Pingxiu He was involved in the pathological diagnosis. Weijun Liu participated in the literature search. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}